Tesamorelin: research overview

The short version

Tesamorelin is a synthetic 44-amino-acid analog of human GHRH, with one chemical modification at its N-terminus (a trans-3-hexenoic acid group) that protects it from rapid enzymatic breakdown. It binds the same GHRH receptor that sermorelin and CJC-1295 target, triggering the pituitary to release pulses of growth hormone and, downstream, raising IGF-1.

Tesamorelin is the only compound on this desk with an FDA approval. That approval — granted in 2010 — is specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a metabolic complication of antiretroviral therapy ^[18]. The evidence base for this indication is solid: multiple randomized controlled trials document significant visceral fat reduction ^[17][19][21]. A 2026 meta-analysis pooling five RCTs found a mean visceral adipose tissue reduction of 27.71 cm2 versus placebo ^[17].

What the approval does not cover — and this matters — is general fat loss, anti-aging, muscle building, or use in people without HIV. All such uses are off-label and investigational. This page covers what the clinical trials actually tested.

What it is

Tesamorelin acetate is a synthetic analog of GHRH(1-44)-NH2 — the full 44-amino-acid GHRH sequence, with a trans-3-hexenoic acid group conjugated to the N-terminus. This N-terminal modification provides resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), extending plasma stability compared to native GHRH. Its empirical formula (free base) is C221H366N72O67S.

It is categorized as a GHRH receptor agonist (growth-hormone-releasing hormone analog) and, in its approved form, is supplied clinically as the acetate salt. Research-grade tesamorelin sold outside the pharmacy supply chain lacks the quality controls of the pharmaceutical product.

Tesamorelin's synonyms in research contexts include TH9507, trans-3-hexenoyl-GHRH(1-44) amide, and GHRH(1-44) analogue. It should not be confused with sermorelin (GHRH 1-29, a shorter fragment) or with CJC-1295 (a tetrasubstituted hGRF(1-29) analog with different stabilizing chemistry).

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor (GHRH-R) on anterior-pituitary somatotroph cells, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade. This stimulates synthesis and pulsatile secretion of endogenous GH. Downstream, GH drives hepatic production of IGF-1, and together GH and IGF-1 promote lipolysis — the breakdown of stored fat — preferentially in visceral adipose tissue.

Because tesamorelin works by amplifying the body's own pulsatile GH rhythm rather than by supplying exogenous GH, physiologic feedback through somatostatin and IGF-1 remains intact ^[17]. This mechanistic difference from direct GH injection is why clinical studies have found tesamorelin's glucose effects to be relatively modest compared to what high-dose recombinant GH produces ^[20].

In a study of 13 healthy men given tesamorelin at 2 mg/day for 2 weeks, mean overnight GH rose by 0.5 ug/L (P=0.004) and IGF-1 increased by 181 ug/L (P<0.0001), while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected ^[20].

What the research shows

Meta-analysis of five RCTs in HIV-associated lipodystrophy (2026). The most recent and comprehensive summary pooled five randomized controlled trials in HIV-positive adults with antiretroviral-related lipodystrophy. Tesamorelin reduced visceral adipose tissue by a mean of 27.71 cm2 (95% CI -38.37 to -17.06; P<0.001), trunk fat by 1.18 kg, and hepatic fat fraction by 4.28%, while lean body mass increased by 1.42 kg — all statistically significant, without serious adverse events in the pooled analysis ^[17].

JAMA RCT — visceral fat and liver fat (HIV adults, n=50, 2014). A 6-month JAMA-published randomized trial in 50 antiretroviral-treated adults with HIV found tesamorelin at 2 mg/day produced a treatment effect of -42 cm2 in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) ^[19]. This was one of the pivotal trials documenting liver fat reduction in addition to visceral fat reduction.

52-week program — sustained effects and reaccumulation (HIV adults, 2008). A 52-week study (n=273 tesamorelin, n=137 placebo) documented sustained visceral fat reduction of approximately 18% over the full year (P<0.001 versus baseline). Glucose parameter changes over 52 weeks were not clinically significant. Critically, upon discontinuation, visceral fat reaccumulated — benefits are contingent on continued administration ^[21].

GH pulsatility and insulin sensitivity in healthy men (n=13, 2011). In healthy men given tesamorelin at 2 mg/day for 2 weeks, mean overnight GH increased significantly and IGF-1 rose substantially, while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected — preserving the favorable glucose profile found in the HIV trials ^[20].

LiverTox safety classification (NIH, 2018). The NIH LiverTox monograph for tesamorelin assigns it a likelihood score of E (unlikely cause of clinically apparent liver injury), noting no attributable liver-injury cases have been reported and no de novo serum enzyme elevations were observed in trials ^[18].

GHRH-analog class review (2025). The Nature Reviews Endocrinology synthesis covers tesamorelin within the broader GHRH-analog pharmacology landscape, including its mechanistic rationale and clinical positioning ^[8].

Reported effects, cautions and safety

Unlike the other three compounds on this desk, tesamorelin has a substantial clinical trial record in humans, so much of what can be said about effects and safety comes from controlled studies rather than community reports alone.

From clinical trials. The most consistently documented clinical effect is significant visceral fat reduction in HIV-positive adults with lipodystrophy ^[17][19][21]. Lean body mass increases modestly. Hepatic fat fraction decreases. Adverse events in trials were predominantly mild: injection-site reactions, peripheral edema, and arthralgias. Glucose effects over 52 weeks were not clinically significant in the HIV trials ^[21], though the mechanistic concern about GH-induced insulin resistance is real and monitoring is warranted in individuals with prediabetes or dysglycemia. Active malignancy is a labeled contraindication given the GH/IGF-1 axis's mitogenic potential.

Key cautions. The FDA approval is specific to HIV-associated lipodystrophy — generalizability to non-HIV populations wanting visceral fat reduction is mechanistically plausible but not established by large RCTs. Benefits do not persist after discontinuation: visceral fat reaccumulates within weeks of stopping ^[21]. Long-term oncologic safety data are limited; the 52-week trials showed no excess malignancy signal, but that window is short. Cognitive findings are mixed: one trial in older adults showed executive-function benefit ^[13], but a 2025 HIV cognition trial did not demonstrate significant neurocognitive improvement over standard care. Research-grade material lacks the quality assurance of the approved pharmaceutical product. Tesamorelin is prohibited in sport under WADA S2 in- and out-of-competition.

Where it fits

Tesamorelin is the most clinically grounded compound on this desk, and the only one carrying a current regulatory approval. That approval is narrow — HIV-associated lipodystrophy — and it matters that the pivotal trials were conducted in a specific population on antiretroviral therapy ^[17][19][21]. Extrapolating results to healthy adults seeking body composition changes, cognitive enhancement, or anti-aging effects moves well beyond the evidence base.

Among the four compounds here, tesamorelin is also the most structurally complete GHRH analog: 44 amino acids versus sermorelin's 29, with N-terminal DPP-IV protection rather than CJC-1295's albumin-conjugation chemistry. This makes tesamorelin the pharmacological reference point for what a full-length, stabilized GHRH analog can achieve in terms of GH and IGF-1 stimulation, and the results are mechanistically informative for understanding the entire class ^[8].